21st January 2026 Immuthera appoints Dr. Antionette Moran, Dr. Jason Gaglia, and Dr. Jeffrey Cohen to the Scientific Advisory Board (SAB) January 20, 2026 – Immuthera, the US subsidiary of PolTREG S.A., a leader in innovative immunological therapies for autoimmune disease, has appointed Professor Antoinette Moran, MD, from the Department of Pediatrics Division of Endocrinology and Diabetology at the University of Minnesota; Professor Jason Gaglia, MD, MMSC, from the Joslin Diabetes Center affiliated with Harvard Medical School; and Professor Jeffrey Cohen, MD, from the Mellen Multiple Sclerosis Center at the Cleveland Clinic”, to Immuthera’s Scientific Advisory Board. These are the latest influential figures to join Immuthera, and add to the collective expertise in d diabetology and neuroimmunology established with the initial appointments of Professor Jay Skyler, MD, MACP, FRCP; Professor Desmond Schatz, MD, and Professor Lawrence Steinman, MD. Professor Antoinette Moran’s scientific achievements focus on pioneering research into the treatment and prevention of both type 1 diabetes and cystic fibrosis related diabetes (CFRD). She helped lead research which has transformed guidelines for diagnosing and treating diabetes in its early pre-clinical and new onset stages. Among other things, her work has influenced the approach to the screening and monitoring of individuals at risk for type 1 diabetes including development of risk prediction models, and she has led clinical trials designed to protect beta cell function and slow progression of the disease such as the recent verapamil trial (CLVer). Her CFRD research has led to international diagnosis and treatment standards. “From the beginning of my career, I have been a proponent of introducing screening tests to identify children at risk of diabetes, for the purpose of discovering therapies that might reduce this risk. Immuthera and PolTREG’s approach to treat presymptomatic Stage 1 and Stage 2 children in the US with Tregs is based on promising early safety and efficacy data, and complimented by the fact that they have already started this study in Europe in Stage 1 T1D patients. The experimental use of Tregs in children is appropriate given the extensive safety data associated with the Tregs and the fact that the disease progresses most rapidly in the young. Tregulatory cell therapy may prevent the progression of T1D in these children, allowing them to delay or potentially even avoid the need for insulin therapy, which would be a significant advancement in the treatment and ultimate prevention of T1D,” Says Dr. Antoinette Moran. Professor Jason Gaglia is the Section Head Clinical, Behavioral, and Outcomes Research at Joslin Diabetes Center, a Harvard Medical School affiliate, where he manages the Hood Center, which focuses on the prevention of childhood diabetes, and serves as the co-director of the Joslin clinical translational research core. Dr. Gaglia is also the clinical lead for the Stage 1 T1D clinical program at T1D TrialNet, an NIDDK/NIH funded clinical trial network at the forefront of T1D research, testing ways to slow down and prevent disease progression. He has served on advisory boards, participated in expert workshops, and provided education for organizations including BT1D, ADA, C-path, and the FDA. Prior industry roles include Vice President of Clinical Science at Semma Therapeutics, acquired by Vertex Pharmaceuticals. His research combines immunology with clinical research in diabetes. His research interests include autoimmune mechanisms and the advancement of therapies that prevent and halt the progression of type 1 diabetes by targeting immune system dysfunction. “I’m delighted to join the Scientific Advisory Board of Immuthera at this pivotal time for T-regulatory cell therapeutics. The company’s focus on harnessing and engineering Tregs to restore immune balance represents a transformative approach to treating autoimmune diseases like type 1 diabetes, where dysregulated immune responses drive disease progression. Throughout my career at Joslin, I’ve been committed to understanding immune mechanisms in diabetes and developing immune-modulating strategies that can protect pancreatic function. Immuthera’s innovative Treg platforms—building on clinically validated cell therapy approaches and novel engineered modalities—offer a real opportunity to move beyond symptomatic care toward restoring tolerance in autoimmunity. I look forward to contributing my clinical and translational experience in diabetes and immunobiology, helping to shape development strategy and accelerate safe, effective Treg therapies that could ultimately change the trajectory of autoimmune diseases,” Says Dr. Jason Gaglia. Professor Jeffrey Cohen is the Director of Experimental Neurotherapeutics at the Mellen Multiple Sclerosis Center at the Cleveland Clinic. He has held leadership positions in numerous multi-center clinical trials, such as ACT (a combination trial with Avonex), the Phase III TRANSFORMS study of fingolimod (a new oral treatment for multiple sclerosis), and the IMPACT study, which was the first to utilize the MS Functional Composite test as a primary outcome measure in clinical trials. He is also co-editor of the textbook “Multiple Sclerosis Therapeutics.” His work has significantly influenced the design of MS clinical trials, therapeutic strategies, and new cell therapies, making him a key figure in the development of MS research. “MS is an area where many breakthrough discoveries have been made and new drugs have been introduced over the course of my lifetime, and I have had the great honor of participating in this process. However, significant innovation is still needed because the drugs we have, although increasingly better, still leave our patients with much suffering. I actively participated in large clinical trials that resulted in the availability of modern drugs such as Fingolimod and Avonex. I have great hopes for cell therapy and hope to be able to actively support the path PolTREG must take so that Immuthera therapeutics can truly help patients in the United States and around the world,” says Dr. Jeffrey Alan Cohen. “We are excited and honored to add Drs. Moran, Gaglia, and Cohen to our SAB. Collectively, this group of six renowned scientists provides Immuthera and parent company PolTREG, with unparalleled technical, clinical, and translational experience in Diabetes and Neuroinflammatory Autoimmune diseases. Professor Moran’s area of expertise is directly relevant to the innovative solutions developed by PolTREG. We are very proud that such a distinguished expert is joining the Scientific Advisory Board. Dr. Moran’s input has already been transformative for the approach and design of our presymptomatic, Stage 1 and Stage 2, Type 1 Diabetes program in the United States. Her input was invaluable leading up to our highly successful FDA Pre-IND meeting on July 24th 2025 Further, Professor Moran’s experience in setting new standards of practice will be particularly valuable for the development of our groundbreaking, clinically derived, and peptide-based in-vitro antigen specific Treg immunotherapy that could inhibit the development of diabetes in children at risk,” says Prof. Piotr Trzonkowski, CEO and Co-Founder of PolTREG S.A. Immuthera’s SAB also consists of: Dr. Jay Skyler, Professor of Medicine, Pediatrics, & Psychology, Division of Endocrinology Diabetes & Metabolism, Department of Medicine, Leonard M. Miller School at the University of Miami. Dr. Desmond Schatz, Professor of Pediatrics, Medical Director of the Diabetes Institute and Director of the Clinical Research Center at the University of Floriday, Gainesville. Dr. Lawrence Steinman, George A. Zimmermann Professor and Professor of Pediatrics. Professor of Neurology and Neurological Sciences, Pediatrics, and Genetics. Stanford University. Abbreviations list: NIH (National Institutes of Health), NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases), BT1D (Breakthrough Type 1 Diabetes), ADA (American Diabetes Association), C-path (Critical Path Institute), FDA (U.S. Food and Drug Administration). About Immuthera: Immuthera is pioneering novel cell-based therapies for clinical development in the United States and Canada. Immuthera will be clinically developing assets initially developed by PolTREG under the US FDA regulatory framework and assets licensed from US institutions. Immuthera will have full access to PolTREG’s Research and Development capabilities and asset pipeline. Immuthera is currently seeking investment to pursue the manufacture and clinical development of these assets in the United States. More information at: https://immuthera.bio/ About PolTREG: PolTREG is a global leader in developing autoimmune therapies based on T-regulatory cells (Tregs). Its lead product, PTG-007, autologous Treg treatment for early-onset Type-1 Diabetes (T1D) is ready for Phase 2/3 clinical testing, for which the company is seeking a partnership. PolTREG has established a robust platform encompassing a wide range of cell therapy approaches, including CAR-Tregs, multi-edited, allogeneic CAR-Tregs, and In-vivo Antigen-Specific Tregs. More information at: https://poltreg.com/ For additional information please contact: Media contact:Michał Wierzchowski, cc groupTel.: +48 531 613 067michal.wierzchowski@ccgroup.pl Contact for investors: ir@poltreg.comAgata Dzięciołowska, cc groupTel.:+48 606 205 119agata.dzieciolowska@ccgroup.pl